Use of totally implantable central venous access port via the basilic vein in patients with thoracic malignancies

[1]  S. Loibl,et al.  Management of venous port systems in oncology: a review of current evidence. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  F. de Marinis,et al.  Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. , 2008, The oncologist.

[3]  A. Bodenham,et al.  Cephalic vein cut-down verses percutaneous access: a retrospective study of complications of implantable venous access devices. , 2007, American journal of surgery.

[4]  L. Jablon,et al.  Cephalic vein cut-down verses percutaneous access: a retrospective study of complications of implantable venous access devices. , 2006, American journal of surgery.

[5]  A. Davies,et al.  The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  D. Chan,et al.  An alternative technique for totally implantable central venous access devices. A retrospective study of 1311 cases. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  C. Seiler,et al.  Surgical technique for totally implantable access ports (TIAP) needs improvement: A multivariate analysis of 400 patients , 2006, Journal of surgical oncology.

[8]  A. Toro,et al.  External Jugular Vein Cutdown Approach, as a Useful Alternative, Supports the Choice of the Cephalic Vein for Totally Implantable Access Device Placement , 2005, Annals of Surgical Oncology.

[9]  H. Liebman,et al.  Thromboembolic complications of cancer: Epidemiology, pathogenesis, diagnosis, and treatment , 2003, American journal of hematology.

[10]  P. Saip,et al.  Totally implantable venous-access ports: local problems and extravasation injury. , 2002, The Lancet. Oncology.

[11]  R. Paz-Fumagalli,et al.  Risk of deep venous thrombosis associated with chest versus arm central venous subcutaneous port catheters: a 5-year single-institution retrospective study. , 2002, Journal of vascular and interventional radiology : JVIR.

[12]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[13]  E. Dauden,et al.  Skin necrosis from extravasation of Vinorelbine * , 1998, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  S. Povoski.  A Prospective Analysis of the Cephalic Vein Cutdown Approach for Chronic Indwelling Central Venous Access in 100 Consecutive Cancer Patients , 2000, Annals of Surgical Oncology.

[15]  P. Lara.  Malignant thymoma: current status and future directions. , 2000, Cancer treatment reviews.

[16]  H. Kock,et al.  Implantable Vascular Access Systems: Experience in 1500 Patients with Totally Implanted Central Venous Port Systems , 1998, World Journal of Surgery.

[17]  D. Coit,et al.  Subcutaneously implanted central venous access devices in cancer patients , 1997, Cancer.

[18]  F. Largiadèr,et al.  Catheter fracture: A rare complication of totally implantable subclavian venous access devices , 1996, Journal of surgical oncology.